Advancing animal testing alternatives
The emerging paradigm: AI prediction → cell models → organoids/chips → minimal animal → human
Several approaches have emerged to reduce the demand on animal models for drug testing. Researchers are rapidly moving beyond traditional animal models by building human-relevant testing systems that better reflect real biology. These include human cell–based models such as primary cells and stem cell–derived tissues, as well as more advanced 3D systems like organoids and spheroids that recreate aspects of organ structure and function. Technologies such as organ-on-a-chip add another layer of realism by simulating dynamic physiological processes—like blood flow or breathing—within microfluidic devices. Alongside these lab-based methods, scientists are increasingly using computational models and AI to predict drug behavior, supported by high-throughput screening and “omics” approaches that provide deep molecular insight. Rather than fully replacing animal studies, these alternatives are converging into a hybrid, human-first testing paradigm. Early-stage discovery often begins with in silico modeling and human cell systems, followed by validation in organoids or chip-based platforms, and in some cases limited animal testing before moving into human trials. This integrated approach improves predictive accuracy, reduces cost and time, and addresses ethical concerns, while also aligning more closely with human physiology. As regulatory agencies begin to recognize these methods, they are poised to become a core foundation of next-generation drug development and biotech innovation.